Anthropic puts Claude inside six drug developers' real pipelines, and a rare muscular dystrophy antibody reaches about twice the peak force and grip strength of vehicle-treated mice
Anthropic's life sciences team has formed deep research partnerships with six organizations developing medicines, BigHat Biosciences, Bristol Myers Squibb, Divergence Labs, Enveda, Generate Biomedicines and The Column Group, and has begun drug discovery of its own, with Claude handling target assessment, molecule design, manufacturing paperwork checks and trial planning across the drug development process. Its acquired one-person company Mithril Medicine used Claude to coordinate 11 external labs and took a bispecific bridging antibody for LAMA2-related congenital muscular dystrophy from idea to mouse results in under 18 months, where the tetravalent construct gave roughly twice the peak force and grip strength of vehicle-treated mice. Most of this work remains preclinical.